Conspectus
Antimicrobial
resistance to existing antibiotics represents one
of the greatest threats to human health and is growing at an alarming
rate. To further complicate treatment of bacterial infections, many
chronic infections are the result of bacterial biofilms that are tolerant
to treatment with antibiotics because of the presence of metabolically
dormant persister cell populations. Together these threats are creating
an increasing burden on the healthcare system, and a “preantibiotic”
age is on the horizon if significant action is not taken by the scientific
and medical communities. While the golden era of antibiotic discovery
(1940s–1960s) produced most of the antibiotic classes in clinical
use today, followed by several decades of limited development, there
has been a resurgence in antibiotic drug discovery in recent years
fueled by the academic and biotech sectors. Historically, great success
has been achieved by developing next-generation variants of existing
classes of antibiotics, but there remains a dire need for the identification
of novel scaffolds and/or antimicrobial targets to drive future efforts
to overcome resistance and tolerance. In this regard, there has been
no more valuable source for the identification of antibiotics than
natural products, with 69–77% of approved antibiotics either
being such compounds or being derived from them.
Our group has
developed a program centered on the chemical synthesis
and chemical microbiology of marine natural products with unusual
structures and promising levels of activity against multidrug-resistant
(MDR) bacterial pathogens. As we are motivated by preparing and studying
the biological effects of these molecules, we are not initially pursuing
a biological question but instead are allowing the observed phenotypes
and activities to guide the ultimate project direction. In this Account,
our recent efforts on the synoxazolidinone, lipoxazolidinone, and
batzelladine natural products will be discussed and placed in the
context of the field’s greatest challenges and opportunities.
Specifically, the synoxazolidinone family of 4-oxazolidinone-containing
natural products has led to the development of several chemical methods
to prepare antimicrobial scaffolds and has revealed compounds with
potent activity as adjuvants to treat bacterial biofilms. Bearing
the same 4-oxazolidinone core, the lipoxazolidinones have proven to
be potent single-agent antibiotics. Finally, our synthetic efforts
toward the batzelladines revealed analogues with activity against
a number of MDR pathogens, highlighted by non-natural stereochemical
isomers with superior activity and simplified synthetic access. Taken
together, these studies provide several distinct platforms for the
development of novel therapeutics that can add to our arsenal of scaffolds
for preclinical development and can provide insight into the biochemical
processes and pathways that can be targeted by small molecules in
the fight against antimicrobial-resistant and -tolerant infections.
We hope that this work will s...